Skip to main content
Year archive

Genmab — 2019 filings

All 213 regulatory filings released by Genmab (GMAB) in 2019, sourced directly from the official regulator.

213 Filings
2019 Period
2019 filings (213)
Filing Released Lang
6-K
Foreign Filer Report
2019-12-20 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2019-12-20 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2019-12-20 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2019-12-20 English
6-K
Foreign Filer Report
2019-12-19 English
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
Regulatory Filings
2019-12-19 English
Regulatory Filings 2019
Regulatory Filings
2019-12-19 English
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
M&A Activity
2019-12-19 English
6-K
Foreign Filer Report
2019-12-17 English
6-K
Foreign Filer Report
2019-12-13 English
CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-12-13 English
Regulatory Filings 2019
Regulatory Filings
2019-12-13 English
CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-12-13 English
6-K
Foreign Filer Report
2019-12-06 English
6-K
Foreign Filer Report
2019-12-06 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2019-12-05 English
Director's Dealing 2019
Director's Dealing
2019-12-05 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2019-12-05 English
Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Employees in Genmab
Remuneration Information
2019-12-05 English
6-K
Foreign Filer Report
2019-12-05 English
Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen
Regulatory Filings
2019-12-05 English
Regulatory Filings 2019
Regulatory Filings
2019-12-05 English
Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen
Regulatory Filings
2019-12-05 English
6-K
Foreign Filer Report
2019-11-19 English
Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-11-19 English
Regulatory Filings 2019
Regulatory Filings
2019-11-19 English
Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-11-19 English
6-K Filing
Foreign Filer Report
2019-11-13 English
6-K
Foreign Filer Report
2019-11-12 English
6-K
Foreign Filer Report
2019-11-12 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2019-11-12 English
Director's Dealing 2019
Director's Dealing
2019-11-12 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing
2019-11-12 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-11-12 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-11-12 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-11-12 English
6-K
Foreign Filer Report
2019-11-06 English
Genmab Announces Financial Results for the First Nine Months of 2019
Report Publication Announcement 9M 2019
2019-11-06 English
6-K
Foreign Filer Report
2019-10-30 English
David Eatwell to Retire as Chief Financial Officer of Genmab
Board/Management Information
2019-10-30 English
Board/Management Information 2019
Board/Management Information
2019-10-30 English
David Eatwell to Retire as Chief Financial Officer of Genmab
Board/Management Information
2019-10-30 English
Genmab’s Financial Calendar for 2020
Report Publication Announcement
2019-10-30 English
6-K
Foreign Filer Report
2019-10-22 English
6-K
Foreign Filer Report
2019-10-18 English
CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-10-18 English
CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Legal Proceedings Report
2019-10-18 English
CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-10-18 English
Legal Proceedings Report 2019
Legal Proceedings Report
2019-10-18 English
6-K
Foreign Filer Report
2019-10-17 English
6-K
Foreign Filer Report
2019-10-15 English
Earnings Release 2019
Earnings Release Q3 2019
2019-10-15 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019
Earnings Release Q3 2019
2019-10-15 English
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Share Issue/Capital Change
2019-10-11 English
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Remuneration Information
2019-10-11 English
6-K
Foreign Filer Report
2019-10-02 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-10-01 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-10-01 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-10-01 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-10-01 English
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma
Regulatory Filings
2019-09-26 English
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma
Earnings Release FY 2019
2019-09-26 English
6-K
Foreign Filer Report
2019-09-26 English
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma
Regulatory Filings
2019-09-26 English
Regulatory Filings 2019
Regulatory Filings
2019-09-26 English
6-K
Foreign Filer Report
2019-09-13 English
6-K
Foreign Filer Report
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings
2019-09-13 English
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
Report Publication Announcement
2019-09-13 English
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
Report Publication Announcement
2019-09-13 English
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
Report Publication Announcement
2019-09-13 English
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
Report Publication Announcement
2019-09-13 English
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
Investor Presentation
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings
2019-09-13 English
Earnings Release 2019
Earnings Release Q3 2019
2019-09-13 English
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
Regulatory Filings
2019-09-13 English
Regulatory Filings 2019
Regulatory Filings
2019-09-13 English
6-K
Foreign Filer Report
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings
2019-08-30 English
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Regulatory Filings
2019-08-30 English
Earnings Release 2019
Earnings Release Q3 2019
2019-08-30 English
6-K
Foreign Filer Report
2019-08-22 English
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
Regulatory Filings
2019-08-22 English
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
Regulatory Filings
2019-08-22 English
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
Regulatory Filings
2019-08-22 English
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
Regulatory Filings
2019-08-22 English
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
Regulatory Filings
2019-08-22 English
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
Regulatory Filings
2019-08-22 English
Legal Proceedings Report 2019
Legal Proceedings Report
2019-08-22 English
6-K
Foreign Filer Report
2019-08-21 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-08-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-08-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-08-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-08-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-08-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-08-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-08-20 English
6-K
Foreign Filer Report
2019-08-14 English
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
Report Publication Announcement
2019-08-14 English
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
Report Publication Announcement
2019-08-14 English
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
Report Publication Announcement
2019-08-14 English
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
Report Publication Announcement
2019-08-14 English
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
Report Publication Announcement H1 2019
2019-08-14 English
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
Interim / Quarterly Report H1 2019
2019-08-14 English
Report Publication Announcement 2019
Report Publication Announcement H1 2019
2019-08-14 English
6-K
Foreign Filer Report
2019-07-23 English
Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
Share Issue/Capital Change
2019-07-23 English
Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
Share Issue/Capital Change
2019-07-23 English
6-K
Foreign Filer Report
2019-07-22 English
Genmab Announces the Completion of its Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
Share Issue/Capital Change
2019-07-22 English
Genmab Announces the Completion of its Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
Share Issue/Capital Change
2019-07-22 English
Major Shareholder Announcement
Major Shareholding Notification
2019-07-19 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-07-19 English
Genmab Announces Full Exercise of Underwriters’ Over-Allotment Option in Initial Public Offering
Share Issue/Capital Change
2019-07-19 English
Share Issue/Capital Change 2019
Share Issue/Capital Change
2019-07-19 English
424B4
Prospectus
2019-07-19 English
Regulatory Filings 2019
Regulatory Filings
2019-07-18 English
Regulatory Filings 2019
Regulatory Filings
2019-07-18 English
Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States
Share Issue/Capital Change
2019-07-18 English
Capital/Financing Update 2019
Capital/Financing Update
2019-07-18 English
F-1MEF
Regulatory Filings
2019-07-18 English
REGISTRATION STATEMENT
Registration Form
2019-07-17 English
FWP
Regulatory Filings
2019-07-16 English
F-1/A
Regulatory Filings
2019-07-16 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2019
Earnings Release Q2 2019
2019-07-16 English
Earnings Release 2019
Earnings Release Q2 2019
2019-07-16 English
POST-EFFECTIVE AMENDMENT NO. 2 TO FORM F-6
Regulatory Filings
2019-07-15 English
Regulatory Filings 2019
Regulatory Filings
2019-07-15 English
8-A12B
Regulatory Filings
2019-07-12 English
Regulatory Filings 2019
Regulatory Filings
2019-07-12 English
FWP
Regulatory Filings
2019-07-12 English
Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulation of Daratumumab
Regulatory Filings
2019-07-12 English
Regulatory Filings 2019
Regulatory Filings
2019-07-12 English
FWP
Regulatory Filings
2019-07-12 English
Genmab Commences Public Offering of American Depositary Shares (ADSs) in the United States
Share Issue/Capital Change
2019-07-09 English
Share Issue/Capital Change 2019
Share Issue/Capital Change
2019-07-09 English
Share Issue/Capital Change 2019
Share Issue/Capital Change
2019-07-09 English
Genmab Announces Positive Topline Results in the Phase II GRIFFIN Study of Transplant Eligible, Newly Diagnosed Patients with Multiple Myeloma Treated with Daratumumab in Combination with Lenalidomide
Regulatory Filings
2019-07-08 English
Earnings Release 2019
Earnings Release Q3 2019
2019-07-08 English
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-06-27 English
Regulatory Filings 2019
Regulatory Filings
2019-06-27 English
Major Shareholder Announcement
Major Shareholding Notification
2019-06-25 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-06-25 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-06-25 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-06-25 English
Major Shareholder Announcement
Major Shareholding Notification
2019-06-19 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-06-19 English
Major Shareholder Announcement
Major Shareholding Notification
2019-06-19 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-06-19 English
Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38
M&A Activity
2019-06-11 English
Capital/Financing Update 2019
Capital/Financing Update
2019-06-11 English
U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-05-30 English
Legal Proceedings Report 2019
Legal Proceedings Report
2019-05-30 English
Regulatory Filings 2019
Regulatory Filings
2019-05-28 English
Genmab Files Registration Statement in the United States for a Proposed Public Offering of American Depositary Shares (ADSs) and Applies for Listing of the ADSs on Nasdaq
Share Issue/Capital Change
2019-05-28 English
Capital/Financing Update 2019
Capital/Financing Update
2019-05-28 English
Capital/Financing Update 2019
Capital/Financing Update
2019-05-28 English
F-1
Regulatory Filings
2019-05-28 English
Regulatory Filings 2019
Regulatory Filings
2019-05-15 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-05-14 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-05-14 English
Regulatory Filings 2019
Regulatory Filings
2019-05-13 English
Regulatory Filings 2019
Regulatory Filings
2019-05-13 English
Regulatory Filings 2019
Regulatory Filings
2019-04-17 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019
Earnings Release Q1 2019
2019-04-16 English
Earnings Release 2019
Earnings Release Q1 2019
2019-04-16 English
Regulatory Filings 2019
Regulatory Filings
2019-04-11 English
Director's Dealing 2019
Director's Dealing
2019-04-04 English
Genmab Announces Phase III Study Exploring Daratumumab as Maintenance Treatment in Newly Diagnosed Multiple Myeloma
Regulatory Filings
2019-04-03 English
Legal Proceedings Report 2019
Legal Proceedings Report
2019-04-03 English
Regulatory Filings 2019
Regulatory Filings
2019-04-02 English
Regulatory Filings 2019
Regulatory Filings
2019-04-02 English
Director's Dealing 2019
Director's Dealing
2019-04-02 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-04-02 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-04-02 English
Regulatory Filings 2019
Regulatory Filings
2019-03-27 English
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-03-27 English
Regulatory Filings 2019
Regulatory Filings
2019-03-26 English
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-03-26 English
Regulatory Filings 2019
Regulatory Filings
2019-03-22 English
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Regulatory Filings
2019-03-22 English
Regulatory Filings 2019
Regulatory Filings
2019-02-28 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-02-26 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2019-02-26 English
Earnings Release 2019
Earnings Release Q1 2019
2019-02-25 English
Genmab Announces Positive Topline Results in Phase III COLUMBA Study of Subcutaneous Daratumumab
Regulatory Filings
2019-02-25 English
Genmab 2018 Annual Report
Report Publication Announcement FY 2018
2019-02-20 English
Annual Report 2018
Annual Report FY 2018
2019-02-20 English
Report Publication Announcement 2018
Report Publication Announcement FY 2018
2019-02-20 English
Regulatory Filings 2019
Regulatory Filings
2019-02-05 English
Legal Proceedings Report 2019
Legal Proceedings Report
2019-01-31 English
Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
Legal Proceedings Report
2019-01-31 English
Legal Proceedings Report 2019
Legal Proceedings Report
2019-01-28 English
Genmab Announces that the patents asserted against DARZALEX® in the United States have been declared invalid by summary judgment.
Legal Proceedings Report
2019-01-26 English
Genmab Announces that the patents asserted against DARZALEX® in the United States have been declared invalid by summary judgment.
Legal Proceedings Report
2019-01-26 English
Regulatory Filings 2019
Regulatory Filings
2019-01-22 English
Genmab Announces Initiation of U.S. FDA Regulatory Submission for Label Expansion of Daratumumab in Combination with Lenalidomide and Dexamethasone in Front Line Multiple Myeloma
Regulatory Filings
2019-01-22 English
Earnings Release 2018
Earnings Release FY 2018
2019-01-22 English
Genmab Announces 2018 Net Sales Figures for DARZALEX® (Daratumumab)
Earnings Release FY 2018
2019-01-22 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-01-17 English
Major Shareholder Announcement
Major Shareholding Notification
2019-01-17 English
Earnings Release 2018
Earnings Release FY 2018
2019-01-08 English
Genmab Achieves USD 75 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen
Regulatory Filings
2019-01-08 English
Director's Dealing 2019
Director's Dealing
2019-01-03 English
Managerial Employees' Transactions
Director's Dealing
2019-01-03 English